Navigation Links
New drug helps allergies

The new drug Clarinex is coming on the market with an advertising blitz--but no proof it works better than older allergy drugs. "Billions of seasonal allergies, one tiny blue pill," proclaim ads from //manufacturer Schering-Plough Corp.

Schering-Plough makes Claritin, the nation's best-selling prescription allergy drug. In November, the Food and Drug Administration is expected to switch Claritin to over-the-counter drug. A month's supply, which now costs about $85, could drop to about $15. Moreover, Schering-Plough's Claritin patent is expected to expire in April, enabling competitors to sell generic versions for even less than $15.

Clarinex is a slightly altered form of Claritin. Within one hour of taking Claritin, the body turns its active ingredient, loratadine, into the active ingredient of Clarinex, desloratadine. Claritin works for between 18 hours and 24 hours. Indeed, Claritin's recommended dose is one pill a day.

With Claritin's $2.8 billion in sales expected to plummet, Schering-Plough is trying to switch patients to Clarinex. In addition to running television, print and Internet ads, the company is selling Clarinex at 20% less than Claritin's price. In order to get Clarinex approved by the FDA, Schering-Plough needed only to prove the drug works better than a placebo, or sugar pill.
'"/>




Page: 1

Related medicine news :

1. Sperm washing helps couples – Breakthrough in focu
2. Patient’s perception of health status helps in better recover
3. New vaccine helps allergy and asthma patients
4. New vaccine helps allergy and asthma patients
5. Now umbilical cord helps in stroke treatment.
6. Spirituality helps lessen arthritic pain
7. New drug helps boost cancer treatment
8. Supplement helps cardiac surgery
9. Antidepressant helps obesity
10. Dopamine helps stroke survivors
11. Radiotherapy helps in colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New drug helps allergies

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Human guinea pigs wary of high-paying medical trials 2
... cases at the Brisbane studios of Australian Broad...ern among its staff. Former news assistant...e among the ABC staff who worked at the now-abando...f compensation for those diagnosed with the diseas...
...e into claims that Paris Hilton received preferent...cility last month. Rumours were rife that t...of probation, was given several privileges by the ...rm instead of a recycled one given to other inmate...
... at a pal's home after her break-up with troubled ...ermodel is staying with celebrity hairdresser and ... Babyshambles frontman's infidelity. Moss ...rned a collection of love letters and poetry which...
...s Center have revealed that genes play a large rol...aste perception. The findings may help re...r that detects sourness in foods and beverages, ju...ds in foods and beverages. In fact, the word acid ...
...ly approved a plan to give families 2,500 euros (3...flagging birth rate . First Deputy Prime M...lowing Friday's cabinet meeting the measure would ...amilies who have had children, including adopted i...
...as urged its six million "sexually active" citizen...ational campaign starts Monday . Health au...tatistics had shown that out of "six million sexua...ow that they are carrying the virus because they h...
Other Medicine News:Health News:More Cancer Testing Urged in Australian TV Studios 2Health News:More Cancer Testing Urged in Australian TV Studios 3Health News:Genes Play Major Role in Determining Individual's Sour Taste Perception 2
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5California Cancer Specialists Medical Group Inc finds clinical benefit in RapidArc 28TM 29 technology and executes strategic vendor agreement with V 58392 1California Cancer Specialists Medical Group Inc finds clinical benefit in RapidArc 28TM 29 technology and executes strategic vendor agreement with V 58392 2Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 1Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 2Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 3Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 1Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 2Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 3Winnick Family Scholarship Awarded to Ramona Davoudpour at UCLA School of Medicine 58383 4
Finnpipette Fixed Volume, 20ul
Pipetman F1000
Finnpipette Focus Fixed Volume, 1ul
Finnpipette Fixed Volume, 2ul
Medicine Products: